secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zoetis Inc. (ZTS)
CIK:        0001555280
Form:       8-K
Filed at:   2024-05-02T23:59:59+00:00
Accession:  0001555280-24-000247
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zoetis Q1 revenue $2.2B (+10% reported, +12% operational); adj EPS $1.38, +5% reported
--------------------------------------------------------------------------------

- Reported net income $599M ($1.31 diluted EPS) +9%; adjusted net income $634M ($1.38 adj EPS) +5% reported, +17% operational.
- US segment revenue $1.2B (+16%), driven by Simparica Trio, Apoquel, Cytopoint, Librela, Solensia.
- International segment revenue $1.0B (+3% reported, +8% operational); companion animal +14% operational.
- FY 2024 guidance raised: revenue $9.05-9.20B, reported EPS $5.34-5.44, adj EPS $5.71-5.81; operational growth 8.5-10.5%.
- Company to sell MFA portfolio and buy a manufacturing site in Australia for vaccine development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1555280/000155528024000247/0001555280-24-000247-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1555280/000155528024000247/zts-20240502.htm
  HTML page:      https://secwatch.observer/filing/0001555280-24-000247

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer